¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"minimal effective dose"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal angle resolution
    ÃÖ¼Ò°¢ºÐÇØ´É
  • minimal bactericidal concentration
    ÃÖ¼Ò»ì±Õ³óµµ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • minimal brain dysfunction
    °æ¹Ì³ú±â´ÉÀå¾Ö
  • minimal change disease
    ¹Ì¼¼º¯È­º´
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
  • minimal identifiable odor
    ÃÖ¼ÒÀνij¿»õ, ÃÖ¼ÒºÐÇØÃë°¢
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • minimal visible angle
    Ãּҽð¢
  • minimal volition period
    ÃÖ¼Ò¼öÃà±â
  • effective alveolar ventilation
    1. À¯È¿ÆóÆ÷ȯ±â 2. À¯È¿ÆóÆ÷ȯ±â·®
  • effective capacity
    À¯È¿¿ëÀû
  • effective charge
    À¯È¿ÀüÇÏ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dose-response relationship
    ¿ë·®¹ÝÀÀ°ü°è
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • minimal blocking concentration
    ÃÖ¼ÒÂ÷´Ü³óµµ
  • minimal inhibitory concentration
    ÃÖÀú¾ïÁ¦³óµµ, ÃÖÀúÀúÁö³óµµ
  • minimal brain dysfunction
    °æ¹Ì³ú±â´ÉÀå¾Ö, ¹Ì¼Ò³ú±â´ÉÀå¾Ö
  • minimal change disease
    ÃÖ¼Òº¯È­ÄáÆÏº´Áõ
  • minimal enhancement
    ¹Ì¹ÌÇÑÁ¶¿µÁõ°­, °æµµÁ¶¿µÁõ°­
  • minimal current gradient
    ÃÖ¼ÒÀü·ù±â¿ï±â, ÃÖ¼ÒÀü·ù°æ»ç
  • minimal tension line
    ÃÖ¼ÒÀå·Â¼±
  • minimal stimulus
    ÃÖ¼ÒÀÚ±Ø
  • minimal angle resolution
    ÃÖ¼Ò°¢ºÐÇØ´É
  • minimal daily requirement
    ÃÖ¼Ò¿µ¾çÇʿ䷮, ÃÖ¼ÒÀÏÀϿ䱸·®
  • minimal identifiable odor
    ÃÖ¼ÒºÐÇØÃë°¢, ÃÖ¼ÒÀνij¿»õ
  • minimal nerve excitability test
    ÃּҽŰæÀڱذ˻ç
  • minimal stimulating test
    ¹Ì¾àÁÖÀÔÀڱؽÃÇè
  • minimal volition period
    ÃÖ¼Ò¼öÃà±â
  • effective capacity
    À¯È¿¿ë·®
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • LD = lethal dose
    Ä¡»ç·®.
  • LD50 (50% lethal dose)
    50% Ä¡»ç·®
  • LD= lethal dose
    Ä¡»ç·®.
  • MTD=> maximum toderance dose
    ÃÖ´ë³»¿ë·®.
  • MTD=£¾maximum tolerance dose
    ÃÖ´ë³»¿ë·®.
  • MTD=ÊÝmaximum toderance dose
    ÃÖ´ë³»¿ë·®.
  • STD= standard test dose
    Ç¥ÁؽÃÇè·®.
  • absorbed dose
    Èí¼ö·®.¹æ»ç¼±Èí¼ö¼±·®(ýåâ¥àÊåÖ).
  • absorbed dose
    Èí¼ö¼±·®
  • absorbed dose conversion factor
    Èí¼ö¼±·®º¯È¯°è¼ö
  • absorbed dose rate
    Èí¼ö¼±·®À²
  • acceptable daily dose : ADD
    ÀÏÀÏÇã¿ë·®(ìéìíúÉé»Õá).
  • acceptable dose
    ¿ëÀμ±·®, ¼ö¿ë¼±·®, Çã¿ë¼±·®
  • adult dosage =a. dose
    ¼ºÀη®, ¼ºÀο뷮.
  • arbitrary dose
    ÀÓÀǿ뷮(ìòëòéÄåÖ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • effective dose 50% =ED 50%
    Áß°£À¯È¿·®, 50%À¯È¿·®.
  • effective dose =ED
    À¯È¿·®.
  • effective dose equivalent
    À¯È¿¼±·®´ç·®
  • maximal effective dose
    ÃÖ´ëÀ¯È¿·®(õÌÓÞêóüùåÖ).
  • mean effective dose =median e. d.
    50% À¯È¿·®(¡­êóüùåÖ).
  • median effective dose =ED50
    50% À¯È¿·®(¡­êóüùåÖ).
  • minimum effective dose
    ÃÖ¼ÒÀ¯È¿·®(¡­êóüùåÖ).
  • minimun effective dose
    ÃÖ¼ÒÀ¯È¿¼±·®
  • cumulative dose ; cumulate dose
    ´©Àû¿ë·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® , [¿¹¹æ] ÁýÀû¼±·®.
  • cumulative dose ; cumulate dose
    ÃàÀû(¿ë)·®, ´©Àû(¿ë)·®, ´©ÀûÁ¶»ç(¿ë)·® .[¿¹¹æ]ÁýÀû¼±·®.
  • dose rate ; dosage rate ; dose per unit time
    ¹æ»ç ÀÓº´,ÇÙÀÇ,¾à¸®¼±·®·ü, ¿ë·®.
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
  • optimal dose ; optimum dose
    ¹æ»ç [¾à¸®,ÇØºÎ,¿¹¹æ]ÃÖÀû·®, ÀûÁ¤·®(ËøËøËâ).
  • optimal dose ; optimum dose
    ÃÖÀû·®, ÀûÁ¤·®(îêïáåÖ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • median hemolytic dose
    Á¤Áß ¿ëÇü·®(ïáñééÁúìÕá)
  • median immunizing dose
    Á¤Áß ¸é¿ª·®(ïáñéØóæµÕá)
  • median infectious dose
    Á¤Áß °¨¿°·®(ïáñéÊïæøÕá)
  • median lethal dose
    Á¤Áß Ä¡»ç·®(ïáñéöÈÞÝÕá)
  • median paralysis dose
    Á¤Áß ¸¶ºñ·®(ïáñ騫ÝöÕá)
  • median tissue culture dose
    Á¤ÁßÁ¶Á÷¹è¾ç·®(ïáñéðÚòÄÛÆå×Õá)
  • median toxic dose
    Á¤Áß µ¶¼º·®(ïáñéÔ¸àõÕá)
  • minimum hemagglutinating dose
    ÃÖ¼ÒÇ÷±¸ÀÀÁý·®(õÌá³úìϹëêó¢Õá)
  • minimum hemolytic dose
    ÃÖ¼Ò¿ëÇ÷·®(õÌá³éÁúìÕá)
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • permissible dose
    Çã¿ë·®(úÉé»Õá)
  • priming dose
    ÀÏÂ÷󸮿뷮(ìéó­ô¥×âéÄÕá)
  • radiation absorbed dose
    ¹æ»ç¼± Èí¼ö·®(Û¯ÞÒàÊýåâ¥Õá)
  • radiation dose
    ¹æ»ç¼±·®(Û¯ÞÒàÊÕá)
  • threshold dose
    ¹®ÅÎ ¼±·®(àÊÕá)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • maximum permissible dose [=MPD]
    ÃÖ´ëÇã¿ë(¼±)·®
  • median lethal dose
    50%Ä¡»ç·®, Æò±ÕÄ¡»ç·®
  • midbreast dose
    À¯¹æÁß¾ÓÁ¶»ç¼±·®
  • permissible internal dose
    ³»ºÎÇã¿ë¼±·®
  • radiation absorbed dose
    ¶óµå, ¹æ»ç¼±Èí¼ö¼±·®
  • relative dose
    ºñ±³Á¶»ç·®, »ó´ëÁ¶»ç·®
  • single dose
    ÀÏȸ·®
  • skin dose
    ÇǺμ±·®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ED early-decision [applicant]; early differentiation; ectodermal dysplasia; ectopic depolarization; eff...
MED median erythrocyte diameter; medical, medication, medicine; Medical Entities Dictionary; minimum eff...
CD cadaver donor; canine distemper; canine dose; carbohydrate dehydratase; carbon dioxide; cardiac dise...
LD labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear...
MD Doctor of Medicine [Lat. Medicinae Doctor]; magnesium deficiency; main duct; maintenance dose; major...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EDE Effective Dose Equivalent
BED biological effective dose
MED minimum effective dose
MED Minimal Erythema Dose
MPD Minimal phototoxic dose
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • effective mass
    À¯È¿ Áú·®
  • effective osmolality
    À¯È¿ »ïÅõÁú ³óµµ
  • effective ratio
    À¯È¿À²
    ¾î´À ÇѰè±îÁö´Â ¾àÁ¦ ¿ë·®°ú À¯È¿À²Àº ºñ·ÊÇÑ´Ù. ÇѰè À̻󿡼­´Â ºÎÀÛ¿ëÀÌ ³ªÅ¸³­´Ù.
  • effective tonicity
    À¯È¿ Àå·Â
  • effective weight
    À¯È¿ Áß·®
  • optimum effective temperature
    ÃÖÀû °¨°¢ ¿Âµµ
  • absorbed dose conversion factor
    Èí¼ö¼±·® º¯È¯ °è¼ö
  • air dose
    °øÁß ¼±·®, °ø±âÁß ¼±·®
    ´Ù¸¥ ¹°Ã¼¿¡ ÀÇÇÑ »ê¶õ¼±À» Á¦¿ÜÇÑ °ø±â ÁßÀÇ ¼±·®. ÀϹÝÀûÀ¸·Î ¹°Ã¼ÀÇ Ç¥¸é¿¡ À־µµ, ¶Ç´Â »ýü Á¶Á÷ ³»ÀÇ ÀÏ Á¡¿¡¼­ÀÇ ¼±·®À¸·Î¼­µµ ¸ðµç »ê¶õ¼±ÀÇ ¿µÇâÀ» ¹Þ±â ¶§¹®¿¡ °øÁß ¼±·®º¸´Ù ¸¹¾ÆÁø´Ù.
  • average dose
    Æò±Õ ¿ë·®, Æò±Õ Á¶»ç·®
  • average maintenance dose
    µð±âÅ»¸®½º Æò±Õ À¯Áö·®
  • basal dose
    ±âº» ¼±·®
  • booster dose
    Ãß°¡ Á¢Á¾·®
  • cumulative absorbed dose
    ´©Àû ¼±·®, ´©Àû Èí¼ö¼±·®
  • cumulative dose
    ÁýÀû ¼±·®, ´©Àû Á¶»ç·®, ´©Àû ¿ë·®, Ãàô ¿ë·®
  • curative dose
    ġȿ·®
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
minimal-change nephrotic syndrome <nephrology> A disorder of the kidneys which largely affects the glomerulus, the blood filtering structure.
This disorder is one common cause of nephrotic syndrome, minimal glomerular changes, in children affecting 2 to 3 children per 100,000 population under age 16 in the USA. Minimal change disease is also seen rarely in adults. The cause is unknown but may be related to an autoimmune illness.
It is marked by oedema, albuminuria, and an increase in cholesterol in the blood, but otherwise with fairly good renal function. Tubular epithelium is vacuolated by cholesterol droplets, but the glomeruli show only that the foot processes of the glomerular epithelial cells are fused, probably secondary to the proteinuria; the cause of the increased glomerular permeability to plasma protein is unknown.
Risk factors include a history for a immune disorder, recent immunisation or a bee sting.
Diagnosis is made by renal biopsy.
Treatment include systemic corticosteroids which are usually quite effective in curing this disease. Other medications include chlorambucil and cyclophosphamide. In most cases, a moderate protein diet (1 gram protein per Kg body weight per day) will be recommended. Salt (sodium) restriction can be helpful to reduce swelling and vitamin D is usually supplemented.
Synonym: lipoid nephrosis
(27 Sep 1997)
minimal deviation melanoma <dermatology, tumour> A malignant melanoma showing less cytologic atypia than is usual in melanoma cells showing asymmetric expansile invasion of the dermis.
(05 Mar 2000)
minimal inhibitory concentration <microbiology, pharmacology> The lowest concentration of antibiotic sufficient to inhibit bacterial growth when tested in vitro.
(05 Mar 2000)
minimal medium <cell culture> The simplest tissue culture medium that will support the proliferation of normal cells.
(18 Nov 1997)
cost-effective A term describing a resource that is available within the time it is needed and is able to meet or reduce electrical power demand at an estimated incremental system cost no greater than that of the least-costly, similarly reliable and available alternative.
(05 Dec 1998)
effective Producing the intended result.
(18 Nov 1997)
effective collision radius <radiobiology> Effective size of a particle equal to the square root of (cross-section/pi). Determines the effective range of interaction of the particle.
(09 Oct 1997)
effective conjugate The internal conjugate measured from the nearest lumbar vertebra to the symphysis, in spondylolisthesis.
Synonym: false conjugate.
(05 Mar 2000)
effective half-life <radiobiology> Time required for a radioactive substance contained in a biological system (such as a person or an animal) to reduce its radioactivity by half, as a combination result of radioactive decay and biological elimination from the system.
(09 Oct 1997)
effective osmotic pressure That part of the total osmotic pressure of a solution that governs the tendency of its solvent to pass across a boundary, usually a semipermeable membrane; it is commonly represented by the product of the total osmotic pressure of the solution and the ratio (corrected for activities) of the number of dissolved particles that do not permeate the bounding membrane to the total number of particles in the solution; equivalent in meaning to tonicity; commonly expressed in equivalent units of osmolality rather than pressure per se.
(05 Mar 2000)
effective refractory period The period during which impulses may appear but are too weak to be conducted; the longest interval between adequate stimuli, falling just short of the time necessary to allow a propagated response to be evoked in a tissue by the second stimulus; it differs from the functional refractory period in that it is a measure of stimulus interval rather than response interval of time.
(05 Mar 2000)
effective renal blood flow The amount of blood flowing to the parts of the kidney that are involved with production of constituents of urine.
(05 Mar 2000)
effective renal plasma flow <physiology> The amount of plasma flowing to the parts of the kidney that have a function in the production of constituents of urine; the clearance of substances such as iodopyracet and p-aminohippuric acid, assuming that the extraction ratio in the peritubular capillaries is 100%.
It is the amount of plasma perfusing the kidney tubules per unit time, generally measured by p-aminohippurate clearance. It should be differentiated from renal plasma flow which is approximately 10% greater than the effective renal plasma flow.
(07 Mar 2000)
effective temperature A comfort index or scale which takes into account the temperature of air, its moisture content, and movement.
(05 Mar 2000)
effective temperature index A composite index of environmental comfort which is compared after exposure to different combinations of air temperature, humidity, and movement.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • effective range
    (°ø)À¯È¿ »ç°Å¸®(»çÁ¤)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á